Further to DrugAlert vol 954, HPS Pharmacies wishes to advise that Mundipharma has decided to reinstate the following eye drops:
Timoptol® Eye Drops
Timolol maleate 0.5%
ARTG 28775
Timoptol®-XE Eye Drops
Timolol maleate 0.5%
ARTG 50306
Cosopt® Eye Drops
Dorzolamide 2% + timolol 0.5%
ARTG 66103
Timoptol® 0.5% eye drops were due to be discontinued in late November 2024. This discontinuation has now been cancelled. However, Mundipharma anticipates a supply interruption from mid-November 2024 to end-February 2025.
Timoptol®-XE 0.5% and Cosopt® were also due to be discontinued this year. These discontinuations have also been cancelled. However, both products are currently experiencing a supply interruption that is expected to resolve by end-February 2025.
Generic alternatives to Cosopt® eye drops are currently experiencing short-term supply interruptions that are expected to resolve by mid-September 2024.
The following internationally registered products have been approved for supply under Section 19A of the Therapeutic Goods Act 1989:
Alternatives to Timoptol®-XE 0.5%:
- Timoptol®-XE 0.5% (South Africa)
- Timoptol®-LA 0.5% (UK)
Alternative to Timoptol® 0.5%:
- Timolol 0.5% w/v eye drops solution Brown and Burk (UK) – S19A approval begins 1/11/2024.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Mundipharma on 1800 188 009 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates